|Event Time:||Saturday April 16, 2016 11:30 am to 6:00 pm|
|Topic(s):||Child Neurology and Developmental Neurology, Research Methodology, Education, and History, Neuroepidemiology, Neuromuscular and Clinical Neurophysiology (EMG), Cerebrovascular Disease and Interventional Neurology, Headache, MS and CNS Inflammatory Disease, Movement Disorders|
|Director(s):||Shafali Jeste MD, FAAN, Rebecca Lehman MD, FAAN|
|Description:||Recognizing that child neurologists are underrepresented at the AAN Annual Meeting and that scientific and educational presentations pertaining to child neurologists are dispersed throughout the week-long conference, a working group of child neurologists collaborated to create an integrated neuroscience session that would meet the educational needs of all child neurologists in a concentrated format. The Frontiers in Child Neurology session seeks to attract child neurologists to the AAN Annual Meeting, deliver high-quality educational and scientific sessions focused on childhood neurological disorders, and provide a platform for child and adult neurologists to examine issues related to transitioning patients with childhood neurologic disorders to the adult health care system. The challenge of transitioning patients from pediatric to adult care has been a neglected area of investigation, and there are few successful models in the literature. In 2011, the primary health care community (AAP, AAFO, ACP) called for subspecialists to outline their role in the medical transition of pediatric patients, and in 2014, the Child Neurology Foundation responded by convening an interdisciplinary panel—including child and adult neurologists—to examine the role of child neurologists in transitioning youths with neurologic disorders. The panel generated a Consensus Statement, which reviewed the literature and outlined Common Principles—direct or indirect responsibilities of the child neurology team in the transition process—based on the current literature and expert opinion. At the conclusion of the program, attendees will recognize that patients with childhood neurologic disorders must ultimately transition to the adult system of care. They will be able to understand the child neurology team’s role in the transition process as defined by the Common Principles and will identify the transition process as a longitudinal effort, not a one-time handoff. Attendees also will have an appreciation for the way in which the AAN can enhance their knowledge base and connect them with colleagues in the field. This session will lay the foundation for future opportunities in the focused integration of child neurologists, from trainees to junior faculty to senior scientists and clinicians, into the annual Academy meeting. Of note, participants also will receive a “Passport to Child Neurology” that will serve as a quick reference for all child neurology-related offerings throughout the meeting.|
|11:30 AM - 1:00 PM||Careers in Child Neurology: Ask the Experts||Brenda Banwell MD, FAAN, Shafali Jeste MD, FAAN, Karen C. Keough MD, Rebecca K. Lehman MD, FAAN, Ann H. Tilton MD, FAAN, David K. Urion MD, FAAN, Rujuta Bhatt Wilson MD|
|1:00 PM - 1:30 PM||Overview of the Child Neurology Foundation’s Transition Project||Lawrence W. Brown MD|
|1:30 PM - 2:00 PM||Common Principles of Transition for the Child Neurology Team||Ann H. Tilton MD, FAAN|
|2:00 PM - 2:30 PM||Review of the Literature||Claudio Melo DeGusmao MD|
|2:30 PM - 3:00 PM||How Can Adult Neurologists Support Successful Transitions?||Gregory D. Cascino MD, FAAN|
|3:00 PM - 3:30 PM||Break/Poster Viewing||None|
|3:30 PM - 5:00 PM||Scientific Presentations||None|
|5:00 PM - 5:30 PM||Poster Blitz Presentations||None|
|5:30 PM - 6:00 PM||Networking Reception||None|
|Brenda Banwell, MD, FAAN||Dr. Banwell has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis.|
|Lawrence W. Brown, MD||Dr. Brown has nothing to disclose.|
|Gregory D. Cascino, MD, FAAN||Dr. Cascino has received personal compensation in an editorial capacity for American Academy of Neurology and the journal Neurology. Dr. Cascino holds stock and/or stock options in Nevro through Mayo Medical ventures.|
|Claudio Melo DeGusmao, MD||Dr. DeGusmao has nothing to disclose.|
|Shafali Jeste, MD, FAAN||Dr. Jeste has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Hoffmann-La Roche Pharmaceuticals.|
|Karen C. Keough, MD||Dr. Keough has received personal compensation for activities with Cyberonics as a speaker.|
|Rebecca K. Lehman, MD, FAAN||Dr. Lehman has nothing to disclose.|
|Ann H. Tilton, MD, FAAN||Dr. Tilton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ipsen Pharma. Dr. Tilton has received research support from Ipsen Pharma.|
|David K. Urion, MD, FAAN||Dr. Urion has nothing to disclose.|
|Rujuta Bhatt Wilson, MD||Dr. Wilson has nothing to disclose.|
|3:30 PM||001||Effects of Vagal Nerve Stimulation in Alternating Hemiplegia of Childhood||
Ashley Helseth , MD, PhD
Dr. Helseth has nothing to disclose.
|3:45 PM||002||Clinical Metabolomic Profiling for the Diagnosis of Neurometabolic Disorders for Global Developmental Delay, Seizures||
Meeta Wagle, MD
Dr. Wagle has nothing to disclose.
|4:00 PM||003||Quantitative Effects of Botulinum Toxin Treatment on the Modified Ashworth Scale and the Tardieu Scale: Results from a Randomized Controlled Study of AbobotulinumtoxinA in Children with Dynamic Equinus Foot Deformity due to Cerebral Palsy||
Ann Tilton, MD, FAAN
Dr. Tilton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ipsen Pharma. Dr. Tilton has received research support from Ipsen Pharma.
|4:15 PM||004||Changes in the Microstructural Connectome Underlie Visual Memory Deficits in the Prematurely Born at Age 16 Years||
Alyssa Thomas, BA
Dr. Thomas has nothing to disclose.
|4:30 PM||005||Pediatric Sport-Related Concussion Education: Effectiveness and Long-Term Retention of the Head Safety Youth Sports (HSYS) Program for Youth Athletes, Ages 11-16||
Dr. Elliott has nothing to disclose.
|4:45 PM||006||Treatment of ADHD in Youth with Epilepsy||
Dr. Lally has nothing to disclose.
|5:00 PM||007||Quantification of Risks of Seizure in Autism||
Jennifer Jaskiewicz , DO
Dr. Jaskiewicz has nothing to disclose.
|5:15 PM||008||Results of North Star Ambulatory Assessments (NSAA) in the Phase 3 Ataluren Confirmatory Trial in Patients with Nonsense Mutation Duchenne Muscular Dystrophy (ACT DMD)||
Dr. Bushby has nothing to disclose.
|3:00 PM||009||Placental Pathology in Neonatal Stroke: A Retrospective Case-Control Study||
Miya Bernson-Leung , MD
Dr. Bernson-Leung has nothing to disclose.
|3:00 PM||010||Emotional Abuse History and Migraine among Young Adults: Results from The Add Health Dataset||
Gretchen Tietjen, MD
Dr. Tietjen holds stock and/or stock options in Johnson & Johnson, Stryker.
|3:00 PM||011||Treatment of Leukoencephalopathy with Cerebral Calcifications and Cysts with Bevacizumab: A Case Report||
Alexander Fay, MD, PhD
Dr. Fay has nothing to disclose.
|3:00 PM||012||Maternal Illness in Pregnancy and Perinatal Exposure to Pesticides Are Associated with Risk for Pediatric Onset MS||
Jennifer Graves , MD,PhD
Dr. Graves has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Celgene. Dr. Graves has received research support from Biogen.
|3:00 PM||013||Predictors of Tic Severity in Post-Childhood Tourette Syndrome: Age-Gender Interaction and Comorbidities||
David Lichter , MBChB, FRACP
Dr. Lichter has nothing to disclose.